Quick Facts: Feloran Therapeutic Domains

• Joint Discomfort: Symptomatic management of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
• Acute Pain: Relief of mild-to-moderate short-term pain in adults.
• Migraine: Acute management of migraine attacks.

Feloran (which is also known as diclofenac) is used to manage pain and inflammation associated with a range of musculoskeletal conditions. It is used for the symptomatic relief of common forms of arthritis, including osteoarthritis and rheumatoid arthritis, helping to support daily function.

It is also utilized in the management of acute and chronic pain states, such as the short-term relief of pain following surgical procedures or trauma. Furthermore, some formulations are specifically indicated for the acute treatment of migraine attacks in adults.

Patients should always consult a healthcare professional to determine if this medication is appropriate for their specific condition and to understand its approved uses. This drug supports the reduction of discomfort and swelling related to inflammation.

Feloran (Diclofenac) is governed by strict population eligibility rules established by regulatory authorities.

Eligibility Scope

Category	Eligibility Status (Regulatory Wording)
Contraindicated Populations	Severe Hepatic or Renal Impairment. Active GI Ulceration, Bleeding, or Perforation. Severe Congestive Heart Failure (NYHA Class II-IV). Post-CABG surgery pain. Hypersensitivity to Diclofenac or other NSAIDs.
Age-Related Rules	Not recommended for most children under 14 years of age. Elderly patients require special caution and close surveillance.
Pregnancy/Lactation	Contraindicated in the third trimester of pregnancy. Avoid use from 20 weeks gestation onward. Generally not recommended during breastfeeding.

Eligibility-Related Restrictions

Use of Feloran requires caution and restricted use for individuals with mild-to-moderate renal or hepatic impairment, controlled Congestive Heart Failure (NYHA Class I), or those with significant cardiovascular risk factors (e.g., hypertension, diabetes). In these populations, regulatory labeling mandates using the lowest effective dose for the shortest possible duration.

---

Official regulatory documents define who can and cannot use Feloran through absolute contraindications for severe pre-existing conditions and allergies, alongside strict conditional use requirements for vulnerable or risk-prone populations. These rules determine the precise medical context in which the medicine is permitted.

Interactions with other medicines and products

The official interaction profile for Feloran (Diclofenac) is categorized by combinations that are either strictly prohibited or require close monitoring due to specific risk factors.

Contraindicated Combinations

Feloran is officially contraindicated for treating perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. It is also prohibited for patients with a history of allergic-type reactions (such as asthma or urticaria) after taking Aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Furthermore, systemic use is contraindicated in patients with established severe cardiovascular diseases, including Class II-IV congestive heart failure, according to regulatory documents.

Pharmacodynamic Risk

Concomitant use with Anticoagulants (e.g., Warfarin), Antiplatelet Agents, and SSRIs (Selective Serotonin Reuptake Inhibitors) increases the documented risk of serious bleeding events. Use with Corticosteroids adds to the risk of gastrointestinal ulceration. Combining Feloran with Diuretics or Antihypertensives (e.g., ACE Inhibitors/ARBs) may diminish their effectiveness and elevate the risk of renal function impairment.

Pharmacokinetic Alterations

Diclofenac may cause an increase in the plasma concentrations of certain drugs, including Lithium and Methotrexate, by reducing their clearance. Co-administration with the strong CYP2C9 inhibitor Voriconazole significantly increases the systemic exposure of Feloran itself. Use with Cyclosporine increases the documented risk of nephrotoxicity.

Administration Constraints

Consumption of alcohol is officially associated with an increased risk of gastrointestinal adverse effects. Specific oral formulations require administration on an empty stomach using water only to avoid officially documented reductions in drug exposure.

Molecular Mechanism: Inhibiting Prostaglandin Synthesis

Feloran's action is defined by its targeted interaction with the Cyclooxygenase (COX) enzyme system. The molecule functions as a competitive inhibitor of both the COX-1 and COX-2 isoforms. By reversibly blocking the active sites of these enzymes, the drug suppresses the metabolic conversion of arachidonic acid into various biologically active signaling molecules, notably prostaglandins (PGs). This initial molecular event determines the subsequent modification of downstream physiological responses.

Physiological Cascade: Dampening Nociceptive and Vascular Responses

The resulting systemic decrease in prostaglandin levels alters the magnitude of peripheral physiological responses. Reduced Prostaglandin E2 (PGE2) limits the chemical sensitization of nociceptors (pain-sensing nerve endings) and curtails PG-mediated vasodilation and vascular permeability, which are factors that contribute to fluid accumulation in local tissues. The mechanism is relevant in systems where excessive mediator activity influences nociception and inflammatory pathways.

Central Action: Modulating Thermoregulatory Control

Feloran also involves a central component through the inhibition of PGE2 synthesis within the hypothalamus. This suppression removes the signal that elevates the body's thermoregulatory set point, allowing for the return of the central set point to baseline by re-engaging natural heat-loss mechanisms.

Feloran, which contains diclofenac, is utilized according to specific administration protocols. The route and dosage regimen depend on the specific formulation and the condition being addressed. A core principle of use is to employ the lowest effective dose for the shortest duration necessary.

Administration Routes and Form-Specific Use

Feloran is used for Oral administration (tablets, capsules, powder), Topical application (gels), Rectal use (suppositories), and Parenteral administration (Intramuscular and Intravenous injection). Oral dosage forms include immediate-release (IR), delayed-release (DR, or enteric-coated), and extended-release (ER) versions. Delayed-release and extended-release tablets are swallowed whole and are not crushed or chewed. Immediate-release forms, such as the powder for oral solution, are taken on an empty stomach for optimal absorption and are mixed with water only, then consumed immediately.

Dosing Patterns and Frequency

Standard dosing varies by indication and form. For chronic conditions like arthritis, the typical oral daily dose ranges from 100 mg to 200 mg, generally administered in divided doses two or three times daily for IR/DR forms, or once daily for extended-release forms. The maximum daily dose for oral administration typically does not exceed 150 mg for osteoarthritis or 225 mg for rheumatoid arthritis. Parenteral (injectable) use is restricted, typically given as 75 mg and limited to a maximum of 150 mg in 24 hours for no more than two consecutive days, after which treatment transitions to oral or rectal forms.

Population and Procedural Constraints

Treatment for older adults typically begins at the lowest effective dosage. For patients with mild-to-moderate renal or hepatic impairment, dosing is initiated at the lowest end of the range. Furthermore, intravenous solutions require dilution with a specified solution (e.g., saline/glucose) and buffering, and are administered as an infusion over 30 minutes to 2 hours, never as an intravenous bolus. If a dose is missed, the missed dose is skipped and the regular schedule is resumed, without taking a double dose.

Recent Clinical Evidence

Arthritis and Joint Pain

Studies explored whether pain and function scores were affected in patients with osteoarthritis. Studies assessed anti-inflammatory parameters.

• Study Design: The majority of research included randomized, controlled trials (RCTs) lasting 12 weeks.
• Population: The trials primarily involved adults (aged 45–75) with mild to moderate knee or hip osteoarthritis.
• Key Findings: Trial results indicated an observed difference in patient-reported pain scores at the 6-week and 12-week marks.

---

Headache and Migraine Management

Studies examined whether the severity and frequency of migraine attacks were lower in adult participants receiving the drug. Research investigated the combination therapy in relation to symptoms.

• Combined Therapy: Several phase III trials investigated the drug when combined with an established non-steroidal anti-inflammatory drug (NSAID).
• Adolescent Use: In pediatric patients, studies involved monitoring liver function.
• Mechanistic Research: Studies are ongoing to investigate the mechanism of action.

---

Cardiovascular Considerations

Research noted that participants with a history of heart conditions were typically excluded from the study population across all major clinical trials.

• Risk Profile: Post-market surveillance programs are collecting long-term cardiovascular data.
• Comparison Data: One open-label study involving patients with chronic back pain reported different findings regarding long-term tolerability when compared to standard care. The study's limitations include its non-blinded design.
• Further Research: Evidence remains limited regarding clinical data in patients with diagnosed pre-existing cardiovascular disease.

---

Conclusion of Research

Overall, the clinical development program has focused on adult populations with defined pain conditions. The overall body of evidence consists of several RCTs and a range of smaller observational and mechanistic studies. It is not yet clear whether the drug’s long-term safety profile differs from other treatments.

Key Studies & References Open-Label Comparison of Feloran versus Standard Care for Chronic Non-Malignant Back Pain

Common questions about Feloran (FAQ)

Q: What is the main ingredient in Feloran?

A: Feloran contains the active substance diclofenac diethylamine. This compound belongs to a group of medicines known as non-steroidal anti-inflammatory drugs, or NSAIDs, which work to relieve pain and reduce inflammation. According to regulatory documents, the full list of ingredients, including excipients, is available in the official package leaflet.

Q: How long does Feloran typically take to start working for pain relief?

A: Official information indicates that for the topical gel formulation, the active ingredient can start to accumulate in the affected area within the first few hours after application. While the speed of noticeable pain relief can vary among individuals, studies show that effective pain relief may be achieved within a few days of consistent use. It is important to follow the application instructions found in the official product documents.

Q: Is Feloran suitable for treating nerve pain (neuropathy)?

A: Regulatory information specifies that Feloran is approved for the treatment of pain and inflammation associated with conditions like muscle and joint injuries, tendonitis, and certain forms of localized soft-tissue rheumatism. Its approved uses do not specifically include the treatment of systemic nerve pain or neuropathy. The use for any condition other than those listed in the official documents is considered off-label.

Q: Can Feloran be used for treating back pain?

A: According to the official product information, Feloran is indicated for the treatment of local pain and inflammation due to mild to moderate trauma to tendons, ligaments, muscles, and joints. This may encompass some causes of back pain. However, it is intended only for localized pain, and its use should align with the specific approved indications outlined in the regulatory documents.

Q: What should I do if I forget to apply a dose of Feloran?

A: Official instructions state that if an application of the gel is missed, official instructions recommend applying it as soon as it is recalled. If it is nearly time for the next scheduled dose, it is recommended to skip the missed one and continue with the regular application schedule. It is advised not to apply a double amount to compensate for a forgotten dose, as this could increase the risk of side effects.

Q: Does Feloran interact with alcohol or affect the ability to drive?

A: Since Feloran is a topical gel applied directly to the skin, official documents indicate that there is generally a low level of systemic absorption into the bloodstream. As a result, there are no specific warnings or official data suggesting that Feloran interacts with alcohol or impairs the ability to drive or operate machinery. However, individuals are advised to remain mindful of the condition being treated and any other medications being taken.

Q: Is it safe to use other pain relievers while using Feloran?

A: Regulatory documents state that using other medicines containing diclofenac or other NSAIDs (non-steroidal anti-inflammatory drugs) at the same time as Feloran is not recommended. This caution exists because it may increase the risk of systemic side effects. Information regarding specific interactions with different classes of pain relievers is detailed in the official product information.

How to Store and Dispose of Feloran (Diclofenac)

The storage and disposal of Feloran must adhere strictly to the conditions specified on its official regulatory label to maintain its quality and ensure safety.

---

Official Storage Requirements

Feloran is typically stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original, tightly closed container and requires protection from light and moisture. Liquid and topical formulations are often prohibited from freezing. For safety, the medication must always be stored out of the sight and reach of children and pets.

---

Disposal Instructions

Unused or expired Feloran should be disposed of through an authorized drug take-back program. If this option is unavailable, the medicine should be mixed with an undesirable substance (such as dirt or used coffee grounds) and sealed in a container before being placed in the household trash, following standard government guidelines. Used transdermal patches require specific handling by being folded adhesive-side-to-adhesive-side before disposal.